SEC Form 4 · accession 0000908662-15-000319
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay R. Luly
Officer — President and CEO · Director
Period of report
Oct 23, 2015
Accepted (ET)
Oct 23, 2015 · 4:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 23, 2015 | M | 22,298 | $1.293 | A | 498,691 | D | |
| Common Stock | Oct 23, 2015 | M | 18,561 | $1.9826 | A | 517,252 | D | |
| Common Stock | Oct 23, 2015 | M | 18,561 | $1.5085 | A | 535,813 | D | |
| Common Stock | Oct 23, 2015 | M | 9,280 | $1.2068 | A | 545,093 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.293 | Oct 23, 2015 | M | 22,298 | D | — | Jun 22, 2016 | Common Stock | 22,298 | 0 | D |
| Stock Option (right to buy)F1 | $1.9826 | Oct 23, 2015 | M | 18,561 | D | — | Jul 10, 2018 | Common Stock | 18,561 | 0 | D |
| Stock Option (right to buy)F1 | $1.5085 | Oct 23, 2015 | M | 18,561 | D | — | Mar 4, 2019 | Common Stock | 18,561 | 0 | D |
| Stock Option (right to buy)F1 | $1.2068 | Oct 23, 2015 | M | 9,280 | D | — | May 24, 2020 | Common Stock | 9,280 | 0 | D |
Explanation of responses
- F1100% of the shares subject to the option are fully vested and exercisable.
Remarks
The reporting person undertakes to provide Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4 above.